A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 535 participants.
Also called NCT01455870
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 535 participants
- Sponsor
- Registry
-
NCT01455870
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Croatia, Denmark, Germany, Latvia
- Registry status
- Completed
Technical summary
Registry record NCT01455870. Randomized; quadruple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2015-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- ITCA 650 60 mcg/day
- Intervention (Drug)
- sitagliptin
- Lead sponsor
- Intarcia Therapeutics
Record details
- Record id
cardio:ct-nct01455870- Content hash
b9f0c036db9da03dfbc17b391abc1925f8e453982dee7c71100c77aaeb84850b